Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Tempest Therapeutics, Inc. (TPST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
14.68+0.10 (+0.69%)
At close: 4:00PM EDT
14.68 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of a presentation on TPST-1495, a selective antagonist of both EP2 and EP4 prostaglandin receptors, at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting taking place November 10-14, 2021 at the Walter

  • GlobeNewswire

    Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche

    Trial to Evaluate TPST-1120/atezolizumab/bevacizumab triplet compared to atezolizumab/bevacizumab aloneSOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the first patient has been dosed in the global randomized Phase 1b/2 clinical study evaluating TPST-1120, Tempest’s small molecule

  • GlobeNewswire

    Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target

    • Russell Vance, PhD joins Tempest Advisory Board SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that it has entered into an exclusive license with the University of California at Berkeley for intellectual property covering a drug target that was discovered in the laboratory of R

Advertisement
Advertisement